EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

Therapeutic efficacy of pyronaridine-artesunate (Pyramax) in treating Plasmodium vivax malaria in the central highlands of Vietnam

Nguyen Duc Manh, Nguyen Van Thanh, Huynh Hong Quang, Nguyen Thi Thanh Van, Nguyen Ngoc San, Nguen Chinh Phong, Geoffrey W Birrell, Kimberly A Edgel, Nicholas J Martin, Michael D Edstein, Marina Chavchich iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00044-24 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Nguyen Duc Manh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Vietnam People's Army Military Institute of Preventive Medicine, Hanoi, Vietnam. Hauptthemen laut MEDLINE: Malaria, Vivax, Naphthyridines, Antimalarials, Artesunate. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: US Department of Defense Health Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence and spread of chloroquine-resistant Plasmodium vivax have necessitated the assessment of alternative blood schizonticidal drugs. In Vietnam, chloroquine-resistant P. vivax malaria has been reported. In an open-label, single-arm trial, the safety, tolerability, and efficacy of pyronaridine-artesunate (Pyramax, PA) was evaluated in Dak Nong province, Vietnam. A 3-day course of PA was administered to adults and children (≥20 kg) infected with P. vivax . Patients also received primaquine (0.25 mg/kg daily for 14 days). PA was well tolerated with transient asymptomatic increases in liver transaminases. The per-protocol proportion of patients with day 42 PCR-unadjusted adequate clinical and parasitological response was 96.0% (95% CI, 84.9%–99.0%, n = 48/50). The median parasite clearance time was 12 h (range, 12–36 h), with a median fever clearance time of 24 h (range, 12–60 h). Single nucleotide polymorphisms (SNPs) as potential genetic markers of reduced drug susceptibility were analyzed in three putative drug resistance markers, Pvcrt-o , Pvmdr1 , and PvK12 . Insertion at position K10 of the Pvcrt-o gene was found in 74.6% (44/59) of isolates. Pvmdr1 SNPs at Y976F and F1076L were present in 61% (36/59) and 78% (46/59), respectively. Amplification of Pvmdr1 gene (two copies) was found in 5.1% (3/59) of parasite samples. Only 5.1% (3/59) of isolates had mutation 552I of the PvK12 gene. Overall, PA rapidly cleared P. vivax blood asexual stages and was highly efficacious in treating vivax malaria, with no evidence of artemisinin resistance found. PA provides an alternative to chloroquine treatment for vivax malaria in Vietnam. CLINICAL TRIALS This study is registered with the Australian New Zealand Clinical Trials Registry as ACTRN12618001429246 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Malaria, VivaxNaphthyridinesAntimalarialsArtesunatePlasmodium vivaxArtemisininsHumansVietnamAdultMaleAdolescentChildFemaleMiddle AgedYoung AdultPrimaquinePolymorphism, Single NucleotideChild, PreschoolProtozoan ProteinsDrug ResistanceMembrane Transport Proteins

Stichwörter der Autor:innen

Plasmodium vivaxPyramaxVietnamantimalarial drug resistancemolecular markerspyronaridine-artesunate

Substanzen

NaphthyridinesAntimalarialsArtesunatepyronaridineArtemisininsPrimaquineProtozoan ProteinsCrt-o protein, Plasmodium vivaxMembrane Transport Proteins

Autor:innen und Institutionen

  • Vietnam People's Army Military Institute of Preventive Medicine, Hanoi, Vietnam.
  • Vietnam Ministry of Health Institute of Malariology, Parasitology and Entomology, Qui Nhon, Vietnam.
  • Australian Defense Force Malaria and Infectious Disease Institute, Brisbane, Australia.
  • U.S. Naval Medical Research Unit INDO PACIFIC, Singapore.

ORCID-Profile: Marina Chavchich

Förderung

  • US Department of Defense Health Program

Zitieren

APA

Manh, N. D., Thanh, N. V., Quang, H. H., Van, N. T. T., San, N. N., Phong, N. C., Birrell, G. W., Edgel, K. A., Martin, N. J., Edstein, M. D., & Chavchich, M. (2024). Therapeutic efficacy of pyronaridine-artesunate (Pyramax) in treating Plasmodium vivax malaria in the central highlands of Vietnam. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00044-24

Vancouver

Manh ND, Thanh NV, Quang HH, Van NTT, San NN, Phong NC, et al. Therapeutic efficacy of pyronaridine-artesunate (Pyramax) in treating Plasmodium vivax malaria in the central highlands of Vietnam. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00044-24

BibTeX
@article{Manh2024,
  author = {Manh, Nguyen Duc and Thanh, Nguyen Van and Quang, Huynh Hong and Van, Nguyen Thi Thanh and San, Nguyen Ngoc and Phong, Nguen Chinh and Birrell, Geoffrey W and Edgel, Kimberly A and Martin, Nicholas J and Edstein, Michael D and Chavchich, Marina},
  title = {Therapeutic efficacy of pyronaridine-artesunate (Pyramax) in treating Plasmodium vivax malaria in the central highlands of Vietnam},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00044-24}
}
Kostenlos starten →